ReviewCurrent topics in microbiology and immunology2009
Recombinant vectors as influenza vaccines.
Review in Current topics in microbiology and immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Viral vector-based influenza vaccines.Human vaccines & immunotherapeutics · 2016Pooled it
- Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.The Lancet. Infectious diseases · 2013Trial
- Article
- Molecular Characterization, Expression and Functional Analysis of ChickenInternational journal of molecular sciences · 2018Article
- Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.Journal of virology · 2016Article
- Virus-vectored influenza virus vaccines.Viruses · 2014Review
- Novel viral vectored vaccines for the prevention of influenza.Molecular medicine (Cambridge, Mass.) · 2012Review
- Article
- Recombinant influenza vaccines.Acta naturae · 2012Article
- Development of adenoviral vector-based mucosal vaccine against influenza.Journal of molecular medicine (Berlin, Germany) · 2011Review
- Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines.Journal of virology · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the advantages and limitations of several different vectors that are currently being tested, and highlights some of the newer viruses being used as recombinant vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.